These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34712363)

  • 1. Circular RNA FOXO3 accelerates glycolysis and improves cisplatin sensitivity in lung cancer cells via the miR-543/Foxo3 axis.
    Zhang Y; Ge P; Zhou D; Xing R; Bai L
    Oncol Lett; 2021 Dec; 22(6):839. PubMed ID: 34712363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CircRNA_100565 contributes to cisplatin resistance of NSCLC cells by regulating proliferation, apoptosis and autophagy via miR-337-3p/ADAM28 axis.
    Zhong Y; Lin H; Li Q; Liu C; Shen J
    Cancer Biomark; 2021; 30(2):261-273. PubMed ID: 33682697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC).
    Zhao Y; Zheng R; Chen J; Ning D
    Cancer Cell Int; 2020; 20():289. PubMed ID: 32655321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
    Zhu X; Han J; Lan H; Lin Q; Wang Y; Sun X
    BMC Cancer; 2020 Dec; 20(1):1190. PubMed ID: 33276753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CircAKT3 inhibits glycolysis balance in lung cancer cells by regulating miR-516b-5p/STAT3 to inhibit cisplatin sensitivity.
    Xu Y; Jiang T; Wu C; Zhang Y
    Biotechnol Lett; 2020 Jul; 42(7):1123-1135. PubMed ID: 32170433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
    Hua L; Zhu G; Wei J
    Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lactate promoted cisplatin resistance in NSCLC by modulating the m6A modification-mediated FOXO3/MAGI1-IT1/miR-664b-3p/IL-6R axis.
    Bo W; Yu N; Wang X; Wang C; Liu C
    Neoplasia; 2024 Feb; 48():100960. PubMed ID: 38184887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
    Wang L; Shang X; Feng Q
    Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
    Pang J; Ye L; Zhao D; Zhao D; Chen Q
    Cell Biol Int; 2020 Dec; 44(12):2416-2426. PubMed ID: 32808744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CircASXL1 Knockdown Restrains Hypoxia-Induced DDP Resistance and NSCLC Progression by Sponging miR-206.
    Yu L; Li J; Peng B; Cai P; Zhao B; Chen Y; Zhu H
    Cancer Manag Res; 2021; 13():5077-5089. PubMed ID: 34234552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXO3 Inhibits the Cisplatin Resistance and Progression of Melanoma Cells by Promoting CDKN1C Transcription.
    Yang C; Yan Z; Sun Z; Hu F; Xu W
    Appl Biochem Biotechnol; 2024 Apr; ():. PubMed ID: 38568329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
    Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4.
    Hu B; Zhang H; Wang Z; Zhang F; Wei H; Li L
    Cancer Biol Ther; 2017 Dec; 18(12):974-983. PubMed ID: 29020498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CircRNA DONSON contributes to cisplatin resistance in gastric cancer cells by regulating miR-802/BMI1 axis.
    Liu Y; Xu J; Jiang M; Ni L; Ling Y
    Cancer Cell Int; 2020; 20():261. PubMed ID: 32581651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.
    Shao N; Song L; Sun X
    Mol Cell Biochem; 2021 Jun; 476(6):2253-2267. PubMed ID: 33570734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
    Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
    Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
    Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
    Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
    Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
    Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
    Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
    Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.